Resistant Hypertension Epidemiology Forecast Report 2022: Focus on US, Germany, Spain, Italy, France, UK, and Japan, 2019-2032 – ResearchAndMarkets.com


DUBLIN–()–The “Resistant Hypertension – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.

The Resistant Hypertension epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries.

The Resistant Hypertension epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Resistant Hypertension epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032.

It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Scope of the Report

  • The Resistant Hypertension report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Resistant Hypertension Epidemiology Report and Model provide an overview of the global trends of Resistant Hypertension in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Resistant Hypertension in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM for the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Resistant Hypertension
  • The report provides the segmentation of the Resistant Hypertension epidemiology

Report Highlights

  • 11-year Forecast of Resistant Hypertension epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Resistant Hypertension
  • Cases of Resistant Hypertension by Mutation Types
  • Resistant Hypertension Cases associated with Clinical Manifestation

Key Assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Key Topics Covered:

1. Key Insights

2. Executive Summary of Resistant Hypertension

3. Resistant Hypertension: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Resistant Hypertension Epidemiology Scenario in the 7MM (2019- 2032)

5.4. United States Epidemiology

5.4.1. Resistant Hypertension Epidemiology Scenario in the United States (2019- 2032)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Resistant Hypertension Epidemiology Scenario in Germany (2019- 2032)

5.5.2. France Epidemiology

5.5.2.1. Resistant Hypertension Epidemiology Scenario in France (2019- 2032)

5.5.3. Italy Epidemiology

5.5.3.1. Resistant Hypertension Epidemiology Scenario in Italy (2019- 2032)

5.5.4. Spain Epidemiology

5.5.4.1. Resistant Hypertension Epidemiology Scenario in Spain (2019- 2032)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Resistant Hypertension Epidemiology Scenario in the United Kingdom (2019-2032)

5.6. Japan Epidemiology

5.6.1. Resistant Hypertension Epidemiology Scenario in Japan (2019- 2032)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Resistant Hypertension Treatment and Management

6.2. Resistant Hypertension Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/qdbjif



Source link

The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy